Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Asia Pacific Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market 26
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market 36
Figure 11. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue 42
Figure 12. Asia Pacific Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%) 42
Figure 13. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, $ bn 43
Figure 14. Asia Pacific Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, $ bn 44
Figure 15. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue 46
Figure 16. Asia Pacific Addressable Market Cap in 2020-2030 by Product, Value ($ bn) and Share (%) 46
Figure 17. Asia Pacific Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn 47
Figure 18. Asia Pacific Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, $ bn 48
Figure 19. Asia Pacific Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, $ bn 49
Figure 20. Asia Pacific Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn 50
Figure 21. Asia Pacific Pharmaceutical Contract Manufacturing Market: Solid Dosage, 2019-2030, $ bn 52
Figure 22. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, $ bn 53
Figure 23. Asia Pacific Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, $ bn 54
Figure 24. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, $ bn 55
Figure 25. Asia Pacific Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, $ bn 56
Figure 26. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue 58
Figure 27. Asia Pacific Addressable Market Cap in 2020-2030 by Phase, Value ($ bn) and Share (%) 58
Figure 28. Asia Pacific Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, $ bn 59
Figure 29. Asia Pacific Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, $ bn 60
Figure 30. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue 62
Figure 31. Asia Pacific Addressable Market Cap in 2020-2030 by Type, Value ($ bn) and Share (%) 62
Figure 32. Asia Pacific Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, $ bn 63
Figure 33. Asia Pacific Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, $ bn 64
Figure 34. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue 66
Figure 35. Asia Pacific Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 66
Figure 36. Asia Pacific Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, $ bn 67
Figure 37. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, $ bn 68
Figure 38. Asia Pacific Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, $ bn 69
Figure 39. Asia Pacific Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, $ bn 70
Figure 40. Asia Pacific Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, $ bn 71
Figure 41. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, $ bn 72
Figure 42. Asia Pacific Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, $ bn 73
Figure 43. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, $ bn 74
Figure 44. Breakdown of APAC Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue 76
Figure 45. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 77
Figure 46. Pharmaceutical Contract Manufacturing Market in Japan, 2019-2030, $ bn 79
Figure 47. Pharmaceutical Contract Manufacturing Market in China, 2019-2030, $ bn 82
Figure 48. Pharmaceutical Contract Manufacturing Market in Australia, 2019-2030, $ bn 84
Figure 49. Pharmaceutical Contract Manufacturing Market in India, 2019-2030, $ bn 86
Figure 50. Pharmaceutical Contract Manufacturing Market in South Korea, 2019-2030, $ bn 88
Figure 51. Pharmaceutical Contract Manufacturing Market in Rest of APAC, 2019-2030, $ bn 90
Figure 52. Growth Stage of Asia Pacific Pharmaceutical Contract Manufacturing Industry over the Forecast Period 92
Asia Pacific pharmaceutical contract manufacturing market will grow by 7.6% annually with a total addressable market cap of $489.1 billion over 2020-2030 owing to the rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity. Highlighted with 38 tables and 53 figures, this 116-page report “Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country. Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Active Pharmaceutical Ingredients (API) • Branded API Manufacturing • Generic API Manufacturing Finished Dosage Formulations (FDF) • Solid Dosage • Oral Liquids • Parenteral/Injectables • Other FDFs Secondary Packaging Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Clinical Manufacturing • Commercial Manufacturing Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Sterile Products • Non-Sterile Products Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More